← Leaderboards
Pamuk Bilsel
Cdi Bioscience, Inc.
$7,632,362
Attributed
$10,299,298
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,299,298 · 8
By mechanism
U01$3,916,610 · 1
R42$1,833,981 · 1
R44$1,489,965 · 1
SB1$1,048,815 · 1
R01$964,804 · 1
R41$824,997 · 2
Top collaborators
- Sally R. Sarawar4 shared
- Vitaliy Gavrilyuk3 shared
- Akiko Iwasaki3 shared
- Yoshihiro Kawaoka1 shared
Others in their field
Top investigators on “Influenza Virus Vaccine”
- Richard Webby · St. Jude Children'S Research Hospital$180,906,285
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$102,809,192
- Ted Ross · University Of Georgia$71,962,304
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$61,899,930
- John Jay Treanor · University Of Rochester$60,722,655
Research focus
Influenza Virus VaccineVaccinesInfluenzavirusVirusCellsInfluenzaT Cell ResponseImmune ResponseElderlyAgedVaccinationImmunityCessation Of LifeSafetyHospitalizationResponseImmunogenicityProductionMorbidity - Disease RateInfluenza A VirusHuman Old Age (65+)MortalityAnimalsInfluenza A Virus, H1n1 Subtype
Grant awards (17)
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2025 · AI · contact PI
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2024 · AI · contact PI
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2023 · AI · contact PI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,304,188
U01 · FY2022 · AI · contact PI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,301,311
U01 · FY2021 · AI · contact PI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,311,111
U01 · FY2020 · AI · contact PI
Development of a novel highly effective influenza vaccine$655,680
R44 · FY2019 · AI · contact PI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$1,087,654
R42 · FY2018 · AI · contact PI
Development of a novel highly effective influenza vaccine$834,285
R44 · FY2018 · AI · contact PI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$746,327
R42 · FY2017 · AI · contact PI
Development of a novel highly effective influenza vaccine$300,000
R41 · FY2015 · AI · contact PI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$224,997
R41 · FY2015 · AI · contact PI
Development of a novel highly effective influenza vaccine$300,000
R41 · FY2014 · AI · contact PI
High-Expression, Rapid Production of Influenza Vaccines in Cell-Based Systems$346,684
R01 · FY2013 · AI
High-Expression, Rapid Production of Influenza Vaccines in Cell-Based Systems$297,690
R01 · FY2012 · AI
A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells$220,126
R43 · FY2012 · AI · contact PI
High-Expression, Rapid Production of Influenza Vaccines in Cell-Based Systems$320,430
R01 · FY2011 · AI